ArticleScientific reports2025
The study of promoting the rational use of sodium valproate in the intensive care unit.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sodium valproate (VPA) is a first-line anti-epileptic drug commonly used in clinical practice, many factors affect the blood concentration of VPA. This study aimed to determine the reasons for low serum levels of Sodium valproate (VPA) in intensive care unit (ICU) patients in our hospital to promote more rational use of VPA in the ICU. Trough concentrations of VPA determined in 57 patients during 2019 and 2020 were retrospectively analyzed. The prescribed medicines for these patients were evaluated for potential drug interactions, the procedures adopted by the nursing staff for enteral tube administration of VPA tablets were also assessed. The average trough concentration of VPA was 33.11 ± 19.14 µg/mL, and a trough concentration within the therapeutic range of 50-100 µg/mL was achieved in 22.8% of 57 patients. Of the 57 patients on VPA, 6 were found to be co-medicated with carbapenem antibiotics, which decreased blood VPA concentrations. Moreover, the incorrect enteral tube administration procedures used by the nurses resulted in significant drug loss. After education and training of the medical staff by clinical pharmacists, these two main adverse factors were obviated. Furthermore, the hospital Pharmaceutical Management Committee adopted the recommendations and introduced VPA injection as a dosage form. After the intervention, data from a total of 88 patients on VPA in the ICU ward were collected from April 2021 to October 2024. The average VPA trough concentration in these patients was 67.69 ± 21.70 µg/mL, which was significantly higher than that before the intervention. The percentage of patients achieving a blood VPA concentration of 50-100 µg/mL increased to 80.7%, the rate of seizure control rose from 22.2% before the intervention to 65.4% after the intervention, the use of VPA injection was favored in severely ill patients to reduce the use of gavage administration. In conclusion, clinical pharmacists promoted the rational use of VPA in the ICU ward, leading to a significant increase in the average trough concentration of VPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.